SCHEMBL1265853

SCHEMBL1265853

CC(C)(c1cc(O)c2c(-c3cccs3)coc2n1)C1CCCCC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
ALDH1A1 P00352 5/20 0.33
HPGD P15428 4/20 0.33
KDM4E B2RXH2 4/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 2/20 0.33
TMIGD3 P0DMS9 3/20 0.32
ADORA2A P29274 2/20 0.32
ADORA1 P30542 2/20 0.32
RPS6KB2 Q9UBS0 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
KAT8 Q9H7Z6 1/20 0.31
TSHR P16473 3/20 0.31
SMARCA2 P51531 1/20 0.31
SMARCA4 P51532 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193263 0.83 MEN1 (0.33) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL1235883 0.83 ALDH1A1 (0.35) MEN1KMT2ARAB9AALDH1A1HPGD
SCHEMBL1236041 0.80 CNR1 (0.33) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL1264611 0.79 ABCB1 (0.40) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL1265031 0.78 MAPT (0.35) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL1265973 0.78 CNR1 (0.33)
SCHEMBL1235880 0.74 CNR2 (0.37) ALDH1A1HPGDKDM4EMAPTMAPK1
SCHEMBL1193185 0.66 MAPT (0.36) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL1193258 0.65 ALDH1A1 (0.31) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL1193324 0.65 MAPT (0.35) NPC1RAB9AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US claimed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US claimed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
WO-2011022692-A2 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE CNR1, CNR2, FAAH MEN1 2840/4885KMT2A 4401/4885NPC1 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.